Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

UK NHS needs to rethink long-term care

MPs call for system change as chronic conditions account for 70 per cent of yearly healthcare spend

- PMLiVE

New NHS CEO announces senior changes

Simon Stevens strengthens leadership within NHS England

UK flag

UK healthcare professionals urged to say ‘no’ to antibiotics

Royal Colleges issues joint statement to members warning of antimicrobial resistance

- PMLiVE

Japan first to approve Roche’s lung cancer drug alectinib

Personalised medicine has same target as Pfizer’s Xalkori and Novartis’ Zykadia

- PMLiVE

Roche wins In-House Team of the Year at Communiqué Awards

"Brave and courageous" UK communications team picks up honour

- PMLiVE

France wants Avastin used in place of Lucentis

Government calls for off-label use of Roche drug in order to reduce spend on eye therapy

Roche - Basel

Roche makes $1.7bn oncology acquisition

Takes over Seragon and its pipeline of investigational breast cancer treatments

- PMLiVE

Erbitux betters Avastin in bowel cancer subgroup

Data backs Merck KGaA drug over Roche’s rival in RAS wild-type metastatic colorectal cancer

- PMLiVE

Novartis and NHS launch mobile eye unit in UK

First of its kind unit to offer 250 clinic slots per week across Surrey, Hampshire and Berkshire

- PMLiVE

Avastin first biologic backed in EU for resistant ovarian cancer

Roche drug recommended in latest round of CHMP opinions

- PMLiVE

Care.Data pilot to be limited to just 100 GP practices

HSCIC admits 'pain' of last 12 months but says health data has transformational potential

- PMLiVE

NICE backs Janssen’s once-daily diabetes drug

Invokana is the tenth treatment recommended in England and Wales to lower blood sugar levels

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links